Atricure Stock Earnings Reports

AtriCure reported a strong start to 2026 with Q1 worldwide revenue of $140–141 million, up ~14% year-over-year, driven primarily by U.S. growth. Key growth drivers were pain management (cryoSPHERE MAX contributing ~70% of pain sales and pain management up 28% Y/Y), open ablation (EnCompass clamp adoption, open ablation +15% Y/Y worldwide; U.S. open ablation +17.3% Y/Y), and appendage management (AtriClip FLEX-Mini and PRO-Mini adoption; appendage management +16% worldwide). The company generated $17.1 million of adjusted EBITDA in Q1 (nearly double year-ago) and posted roughly breakeven EPS. Balance sheet remains healthy with ~$146 million in cash and investments and management expects to be cash flow positive for the year with modestly higher full-year cash generation than 2025. Major clinical and commercial catalysts: BoxX-NoAF enrollment is far ahead of plan (~300 of 960 patients enrolled) with expected completion around year-end (nearly one year ahead), LeAAPS trial ongoing, CE Mark under EU MDR received for FLEX-Mini/PRO-Mini for Europe (planned launches there later this year), and progress on PFA first-in-human work. Management reiterated 2026 guidance: revenue $600–610 million (12–14% growth) and adjusted EBITDA $80–82 million, EPS ~ $0.00–$0.04, adjusted EPS $0.09–$0.15. Near-term headwinds include continued weakness in minimally invasive (hybrid) ablation volumes, lumpiness in some Asia distributor orders, and U.K. uncertainty. Management is increasing near-term R&D spend to accelerate BoxX-NoAF enrollment (incremental to prior plans) but expects to absorb these costs while maintaining guidance.